World Health Organization Issues Warning Over Acute Lack of Obesity Jabs

Under 10% of patients that would benefit from GLP-1 drugs like Wegovy have access to them, warns the global health agency as it publishes its initial recommendations on the medications.

With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for more widespread and fairer availability to GLP-1 medication.

Per forecasts, over two billion are projected to be obese by 2030 without intervention.

"Our latest guidance acknowledges that excess weight is a lifelong illness that can be addressed with thorough and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and distribution challenges are major barriers to widespread availability to the jabs that can aid individuals in losing substantial weight, explains the organization.

Weight-Loss Drug Supply Crisis

Even in the current most favorable case, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – less than 10% of the global need, per the WHO.

The recommendation encourages nations and manufacturers to widen access, by strategies including voluntary licensing.

Exclusive production rights on semaglutide – the main ingredient of a leading brand – is scheduled to end in a number of nations in 2026.

The Way Weight-Loss Jabs Work

GLP-1 drugs imitate a natural hormone to reduce digestion speed, curb appetite and increase feelings of fullness so users consume fewer calories.

Individuals usually see weight reduction after several weeks of beginning the weekly injections.

Evidence points to patients may put most of the weight back on after a year of stopping the drug, because their typical appetite return.

To be above a healthy weight elevates your likelihood for developing medical conditions, such as diabetes, heart disease, stroke, and some malignancies.

Obesity impacts people in all nations and was responsible for millions of fatalities worldwide in 2024, according to the WHO.